BIOS Capital Management, LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001813845

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth Tilt how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q3 2026 · 6 positions · Total reported value $34.17B · Top-10 concentration 100.0% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 16.7% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -18.0% · vs SPY -20.1% · Prev Value $41.67M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -31.8% · vs SPY -34.0% · Latest Value $34.17B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, BIOS Capital Management, LP disclosed 6 equity positions with a combined reported value of $34.17B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt.

The largest disclosed positions as of Q3 2026 were IRD ($17.83B), ACTU ($7.84B), CGTX ($5.76B). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, BIOS Capital Management, LP opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 16.7% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest BIOS Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-17 Award COGNITION THERAPEUTICS INC 25,000 — SEC filing

All insider transactions →

Fund Profile

BIOS Capital Management, LP is an SEC-registered 13F filer based in Fort Worth, TX, United States. As of Q2 2026 it reported 6 US equity positions with a combined value of $41.67M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Firm Snapshot

  • Headquarters: FORT WORTH, TX, United States
  • SEC registration: 801-117544 (status: Approved), registered 2019-10-24
  • Regulatory AUM (Form ADV): $250.90M as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 24 private funds

Portfolio Structure

  • 6 positions · $41.67M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ACTU (ACTUATE THERAPEUTICS INC) at 36.9%
  • Average position size: $6.95M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added, 2 reduced
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased its top holding (IRD) significantly (52.17% vs. 36.33%), suggesting a bullish stance on OPUS GENETICS, while trimming LANTERN PHARMA, indicating selective profit-taking or reduced confidence. No new positions were added. 2. Key moves: Only one reduction: LTRN (LANTERN PHARMA) was reduced by 5.4% (shares fell from 249,397 to 235,895). No additions were made. 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top holdings), with high risk appetite (top 3 holdings hold 92% of value). No passive exposure. 4. Per-holding one-liner: - IRD: OPUS GENETICS INC (biopharma, unverified if clinical-stage). - ACTU: ACTUATE THERAPEUTICS INC (biopharma, unverified if clinical-stage). - CGTX: COGNITION THERAPEUTICS INC (neurodegeneration drugs, unverified if clinical-stage). - RNTX: REIN THERAPEUTICS INC (biopharma, unverified if clinical-stage). - LTRN: LANTERN PHARMA (AI-driven oncology drugs, unverified if clinical-stage). - INAB: IN8BIO INC (infectious disease vaccines, unverified if clinical-stage). 5. Style summary: Concentrated, high-conviction biotech fund with aggressive bets on a few clinical-stage names, trimming only one position amid a quarter of otherwise static holdings.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-16 12:01

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.68M $17.83B 52.17%
52.17%
Hold
2 10.05M $7.84B 22.94%
22.94%
Hold
3 6.00M $5.76B 16.86%
16.86%
Hold
4 2.98M $2.40B 7.02%
7.02%
Hold
5 235.90K $238.25M 0.70%
0.70%
Reduce
6 80.96K $107.67M 0.32%
0.32%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 100% R 100% F1 100% (modelled on 2026-Q2; 6/10 hit)

Historical Backtest (6 quarters)

Avg precision 100% · recall 100% · F1 100% · avg rank error 0.6 · Top-10 turnover 0%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 100% 100% 100% ACTU · LTRN · RNTX · CGTX · INAB · IRD ACTU · IRD · LTRN · RNTX · CGTX · INAB
2025-Q3 100% 100% 100% ACTU · IRD · LTRN · RNTX · CGTX · INAB ACTU · CGTX · IRD · LTRN · RNTX · INAB
2025-Q4 100% 100% 100% ACTU · CGTX · IRD · LTRN · RNTX · INAB ACTU · CGTX · IRD · LTRN · RNTX · INAB
2026-Q1 100% 100% 100% ACTU · CGTX · IRD · LTRN · RNTX · INAB ACTU · IRD · CGTX · RNTX · LTRN · INAB
2026-Q2 100% 100% 100% ACTU · IRD · CGTX · RNTX · LTRN · INAB ACTU · IRD · CGTX · RNTX · LTRN · INAB
2026-Q3 ★ 100% 100% 100% ACTU · IRD · CGTX · RNTX · LTRN · INAB IRD · ACTU · CGTX · RNTX · LTRN · INAB

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did BIOS Capital Management, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, BIOS Capital Management, LP reported 6 equity positions worth $34.17B in aggregate; its largest disclosed positions were IRD ($17.83B), ACTU ($7.84B), CGTX ($5.76B).

How large is BIOS Capital Management, LP's portfolio?

BIOS Capital Management, LP reported $34.17B of long equity holdings across 6 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is BIOS Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bios-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →